Page 6 - Michael Castagna News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be vulnerable to their...

Wedbush initiated coverage on shares of MannKind (NASDAQ:MNKD – Free Report) in a research report released on Monday morning, MarketBeat reports. The firm issued an outperform rating on the biopharmaceutical company’s stock. Wedbush also issued estimates for MannKind’s Q3 2023 earnings at ($0.02) EPS, Q4 2023 earnings at ($0.03) EPS, FY2023 earnings at ($0.10) EPS, […]

MannKind Co. (NASDAQ:MNKD – Get Free Report) CEO Michael Castagna sold 10,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $4.61, for a total transaction of $46,100.00. Following the sale, the chief executive officer now directly owns 2,436,039 shares of the […]

Profund Advisors LLC acquired a new position in MannKind Co. (NASDAQ:MNKD – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 256,293 shares of the biopharmaceutical company’s stock, valued at approximately $1,051,000. A number of other hedge funds and […]

StockNews.com started coverage on shares of MannKind (NASDAQ:MNKD – Free Report) in a report issued on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald boosted their price target on shares of MannKind from $6.50 to $7.50 and […]